GAP1 Family Members Constitute Bifunctional Ras and Rap GTPase-activating Proteins*

Sabine Kupzig[‡1], **Delia Deaconescu**[§1], **Dalila Bouyoucef**[‡], **Simon A. Walker**[¶], **Qing Liu**[¶], **Christian L. Polte**[§],
Oliver Daumke[§], **Toshimasa Ishizaki**[§], **Peter J. Lockyer**[¶], **Alfred Wittinghofer**[§], and **Peter J. Cullen**[‡2]

From the ‡Henry Wellcome Integrated Signaling Laboratories, Department of Biochemistry, School of Medical Sciences, University of Bristol, Bristol BS8 1TD, United Kingdom, §Max-Planck-Institut für Molekulare Physiologie, Postfach 50 02 47, 44202 Dortmund, Germany, and ¶Signaling Programme, The Babraham Institute, Cambridge CB2 4AT, United Kingdom

GAP1[IP4BP] **is a member of the GAP1 family of Ras GTPase-activating proteins (Ras GAPs) that includes GAP1**[m]**, CAPRI, and RASAL. Composed of a central Ras GAP domain, surrounded by amino-terminal C$_2$ domains and a carboxyl-terminal pleckstrin homology/Bruton's tyrosine kinase domain, GAP1**[IP4BP] **has previously been shown to possess an unexpected GAP activity on the Ras-related protein Rap, besides the predicted Ras GAP activity (Cullen, P. J., Hsuan, J. J., Truong, O., Letcher, A. J., Jackson, T. R., Dawson, A. P., and Irvine, R. F. (1995) Nature 376, 527–530). Here we have shown that GAP1**[IP4BP] **is indeed an efficient Ras/Rap GAP, having K_ms of 213 and 42 μM and estimated k_{cat}s of 48 and 16 s^{-1} for Ras and Rap, respectively. For this dual activity, regions outside the Ras GAP domain are required, as the isolated domain (residues 291–569) retains a pronounced Ras GAP activity yet has very low activity toward Rap. Interestingly, mutagenesis of the Ras GAP arginine finger, and surrounding residues important in Ras binding, inhibit both Ras and Rap GAP activity of GAP1**[IP4BP]**. Although the precise details by which GAP1**[IP4BP] **can function as a Rap GAP remain to be determined, these data are consistent with Rap associating with GAP1**[IP4BP] **through the Ras-binding site within the Ras GAP domain. Finally, we have established that such dual Ras/Rap GAP activity is not restricted to GAP1**[IP4BP]**. Although GAP1**[m] **appears to constitute a specific Ras GAP, CAPRI and RASAL display dual activity. For CAPRI, its Rap GAP activity is modulated upon its Ca^{2+}-induced association with the plasma membrane.**

The Ras-like family of small GTPases includes, in addition to the "classic" Ras proteins H-Ras, N-Ras, and K-Ras4A and 4B, the Rap proteins Rap1A, 1B, 2A, and 2B (1–3). These ubiquitously expressed, evolutionarily conserved proteins couple extracellular signals to various cellular responses through an ability to undergo conformational changes in response to the alternate binding of GDP and GTP. The GDP-bound "off" state and the GTP-bound "on" state recognize distinct effector proteins, thereby allowing these proteins to function as binary molecular switches (1–3). Although Ras is the best known and best studied member of the family, Rap1A and 1B have recently attracted considerable attention (3–6).

Rap1 was identified as a protein that could suppress the transformed phenotype of fibroblasts oncogenically transformed by one of the mutated Ras genes, *K-ras* (7). This coupled with Rap1 having an effector domain virtually identical to that of Ras led to a model in which Rap1 was considered to function as an antagonist of Ras by trapping Ras effectors in an inactive complex (4). However, recent analysis has suggested that Rap1 may possess more complex biological functions. Active Rap1 has been implicated in several cellular processes, including superoxide formation, cyclic adenosine monophosphate (cAMP)-induced neurite outgrowth, cell proliferation, integrin-mediated cell adhesion, and secretion (3–6).

As with other small GTPases, the extent and duration of Ras and Rap1 signaling is controlled by the interplay between guanine-nucleotide exchange factors (GEFs),[3] which induce activation by stimulating the exchange of GDP for GTP, and GTPase-activating proteins (GAPs), which modulate inactivation by enhancing the intrinsic GTPase activity. A wide range of GEFs and GAPs for these GTPases have been identified, and in a few instances the mechanisms by which signals originating from activated cell surface receptors converge on these proteins have been mapped. However, for most Ras-like GEFs and GAPs we have a poor understanding of their regulation (8–10).

In mammalian cells, Ras-specific GAPs include p120[GAP], NF1, GAP1 proteins, and the SynGAPs (DAB2IP, nGAP, and Syn GAP). Rap1-specific GAPs comprise Rap GAPs I and II, the SPA-1 family (SPA-1, SPAR, SPAL, E6TP1), tuberin, and DOCK4 (Ref. 11, reviewed in Ref. 8). Although Rap1 is a close homologue of Ras it does not possess the catalytic glutamine residue that is critical for GTP hydrolysis in all other Ras-like GTPases. The mechanism by which Ras and Rap1 GAPs enhance the GTPase activity of their respective GTPase is therefore distinct. For Ras GAPs a catalytic arginine residue, the arginine finger, is supplied by the GAP molecule into the active site of Ras, thereby stabilizing the transition state of the GTPase reaction and increasing the reaction rate by >1,000-fold (12–14). Rap1 GAPs are not related to other GAPs and do not employ a catalytic arginine residue (15, 16); instead, Rap1 GAPs provide a catalytic asparagine, the asparagine thumb, to stimulate GTP hydrolysis (17). It has been proposed that the carboxamide side chain of the asparagine residue has a function similar to the glutamine residue in Ras-like GTPases in stabilizing the relative position of the nucleophilic water and γ-phosphate in the transition complex (17).

The GAP1 family, which comprises GAP1[m], GAP1[IP4BP], CAPRI, and RASAL (18–22), is characterized by a conserved domain structure comprising amino-terminal tandem C$_2$ domains, a highly conserved central Ras GAP domain, and a carboxyl-terminal pleckstrin homology domain that is associated with a Bruton's tyrosine kinase motif (23).

[3] The abbreviations used are: GEF, guanine-nucleotide exchange factor; GST, glutathione S-transferase; CHO, Chinese hamster ovary; DTE, dithioerythritol; HA, hemagglutinin; EGF, epidermal growth factor.

FIGURE 1. **Michaelis-Menten kinetics of the GAP domain of GAP1^{IP4BP}.** *A*, 100 nM GAP1^{IP4BP}-(291–569) were incubated in standard buffer at 25 °C with increasing concentrations of H-Ras[γ-^{32}P]GTP (●) and Rap1A[γ-^{32}P]GTP (■). The *insert* shows the reaction with mutant Rap-(T61Q) (▲) in comparison with wild-type Rap (■). *B*, the data from *panel A* are plotted as k_{cat} in *panel B*. *C* and *D*, 20 μM GAP1^{IP4BP}-(291–569) were used to assay GTP hydrolysis with increasing concentrations of Rap1A[γ-^{32}P]GTP. GTPase activity was monitored by measuring P$_i$ release, and data were evaluated as described under "Materials and Methods." Data are plotted as rates (*C*) or rate constants (*D*).

FIGURE 1—*continued*

Consistent with the presence of the Ras GAP domain all of these proteins have been shown to function as Ras GAP, although each is differentially regulated following receptor stimulation (19, 21, 22, 24, 25). Surprisingly, however, given that these proteins contain no detectable sequence homology with any known Rap GAP, GAP1[IP4BP] is also capable of enhancing the GTPase activity of Rap (19). This protein therefore has dual Ras and Rap GAP activity. In the current study we describe a kinetic characterization of this dual activity and have begun the process of dissecting out the mechanistic details of these activities. In addition, we address whether dual Ras/Rap GAP activity is restricted solely to GAP1[IP4BP] or is a function conserved within other members of the GAP1 family.

MATERIALS AND METHODS

Purification of GTP-binding Proteins—C-terminal-truncated Rap1B (Rap1B C′, residue 1–167) was purified from *Escherichia coli* strain CK600K using the ptac-expression system as described for Ras by Tucker *et al.* (26). After lysis in 32 mM Tris (pH 7.5), 100 μM phenylmethylsulfonyl fluoride, 2 mM EDTA, the supernatant was applied to a Q-Sepharose column equilibrated with 32 mM Tris (pH 7.5), 10 mM MgCl$_2$, 5 mM DTE. After washing with the same buffer, proteins were eluted using a salt gradient (0–300 mM NaCl) in 32 mM Tris (pH 7.5), 10 mM MgCl$_2$, 5 mM DTE. Fractions containing Rap1B C′ were precipitated with ammonium sulfate (3 M final concentration). The pellet was resuspended in 64 mM Tris (pH 7.5), 10 mM MgCl$_2$, 5 mM DTE, 200 μM GDP, 0.4 M NaCl and further purified on a Sephadex 75 gel filtration column. Fractions containing Rap1B C′ were pooled and concentrated using an Amicon concentrator (10-kDa cut-off). Truncated H-Ras-(1–166) was purified as described before (26, 27).

Purification of GAP1[IP4BP]—For stability reasons, full-length wild-type GAP1[IP4BP] was purified as GST fusion protein GST-GAP1[IP4BP], while the mutant full-length GST-GAP1[IP4BP]-(R371A) and the GAP domain construct GST-GAP1[IP4BP]-(291–569) was cleaved from GST. Freshly transformed *E. coli* Rosetta strain was grown in 5 liters of TB medium containing 50 μg/ml ampicillin and 50 μg/ml chloramphenicol at 37 °C. At A_{600} ~0.8, expression was induced by addition of 100 μM isopropyl 1-thio-β-D-galactopyranoside overnight at 18 °C. After lysis by micro-fluidizer (Microfluidics Corp.) in 50 mM Hepes (pH 7.5), 5 mM DTE, 50 mM NaCl, 2.5 mM EDTA, 100 μM phenylmethylsulfonyl fluoride, the extract was applied to glutathione-Sepharose 4-B (Amersham Biosciences) in 50 mM Hepes (pH 7.5), 5 mM DTE, 50 mM NaCl. Following extensive washes, the protein was eluted with buffer containing 30 mM glutathione (pH 7.5). Protein was concentrated using an Amicon concentrator (30-kDa cut-off), and aliquots were snap frozen in liquid nitrogen and stored at −80 °C. Cleavage of GAP1[IP4BP]-(R371A) and GAP1[IP4BP]-(291–569) from GST was performed on the glutathione-Sepharose column with 300–600 units of thrombin (Serva) overnight at 4 °C under continuous circulation (0.5 ml/min). Proteins were eluted with 50 mM Hepes (pH 7.5), 5 mM DTE, 50 mM NaCl. GAP1[IP4BP]-(291–569) was further purified on a Superdex 200 gel filtration column in 50 mM Hepes (pH 7.5), 5 mM DTE, 50 mM NaCl. Proteins were concentrated using an Amicon concentrator (15 and 30-kDa cut-off), and aliquots were snap frozen in liquid nitrogen and stored at −80 °C. Full-length constructs cannot be fully purified and contain additional lower molecular mass bands, most probably derived from proteolytic degradation.

Nucleotide Exchange—200 μM Rap or Ras in 25 mM Tris (pH 7.5), 100 mM NaCl, 5 mM DTE were incubated with 15 mM EDTA, 100 mM ammonium sulfate, and 10 mM GTP (stock 100 mM nucleotide in 1 M Tris, pH 7.5) for 60 min at room temperature. Exchange was terminated by the addition of 25 mM MgCl$_2$. The separation of unbound nucleotides and EDTA from Rap-GTP and Ras-GTP was carried out by washing the proteins several times with buffer using an Amicon concentrator (10-kDa cut-off) at 4 °C. Nucleotide exchange was controlled by reversed-phase high performance liquid chromatography. Radioactive [γ-^{32}P]GTP-bound Rap1 and Ras were prepared by incubating 1.5 mM GTP-bound protein with 20 μCi of [γ-^{32}P]GTP (800 Ci/mmol; Amersham Biosciences) in the presence of 12 mM EDTA for 30 min on ice. The exchange reaction was stopped by the addition of 25 mM MgCl$_2$.

GAP Assay—The GAP-stimulated GTP hydrolysis of Rap1 and H-Ras was assayed by measuring P_i release using the charcoal method. Briefly, increasing amounts of radioactively labeled Rap-GTP and Ras-GTP were added to fixed concentrations of GAP1[IP4BP] proteins at 25 °C in standard buffer (25 mM Tris (pH 7.5), 5 mM MgCl$_2$, 5 mM DTE, 50 mM NaCl) as described before (15). To determine end points of GTP hydrolysis, all Rap-GTP and Ras-GTP were hydrolyzed by addition of a highly concentrated GAP1[IP4BP] solution, and a last aliquot was taken. Initial GTP hydrolysis rates were evaluated by linear regression, and K_m and k_{cat} were determined by Michaelis-Menten equation using the program Grafit (Erithacus software).

GAP Assays of GAP1[IP4BP] Site-directed Mutants—Full-length GAP1[IP4BP] mutants L484A, R485Q, K517E, and K534A were isolated as GST fusion proteins, and analysis of the GAP activities of these mutants was performed under first order kinetics as described by Bottomley *et al.*

FIGURE 2. **Michaelis-Menten kinetics of full-length GAP1[IP4BP].** 5 nM full-length enriched GST-GAP1[IP4BP] were incubated in standard buffer at 25 °C with increasing concentrations of radioactively labeled [γ-^{32}P]GTP Ras (●) (*A*) or Rap-GTP (■) (*A*, *B*) as indicated, and GTP hydrolysis was measured as described in Fig. 1. The GTPase reaction of Rap was also measured with the arginine finger mutant GAP1[IP4BP]-(R371A) (♦) in *panel A* or the T61Q mutant (▲) of Rap in *panel B*.

(28). The particular GTP-binding protein was loaded with [γ-^{32}P]GTP (3000 Ci mmol[−1]; Amersham Biosciences) for 5 min at 25 °C. GTPase activity was assayed at 25 °C by addition of the various GAP proteins to the loaded GTP-binding protein. After 10 min, activity was stopped by addition of 5 mM silicotungstate, 1 mM H$_2$SO$_4$. The liberated [^{32}P]P$_i$ was extracted with isobutanol/toluene (1/1 v/v), 5% (w/v) ammonium

molybdate, 2 M H$_2$SO$_4$, and the upper phase was removed for scintillation counting.

Ras Pulldown Assays—Glutathione *S*-transferase fusion of the Ras-GTP-binding domain from Raf-1 (GST-RBD) was purified from BL21(DE3) *E. coli* cells harboring the plasmid pGEX KG containing the Raf Ras-binding domain (amino acids 1–149). After induction of a bac-

terial culture (A_{600} between 0.4 and 0.6) for 3 h at 37 °C with 1 mM isopropyl-1-thio-β-D-galactopyranoside, cells were lysed by sonication in phosphate-buffered saline containing 1 mM EDTA, 1% Triton X-100, 10 μg/ml of aprotinin, and 10 μg/ml of leupeptin. The lysate was clarified by centrifugation, and the resultant supernatant was stored in aliquots at −80 °C. On the required day, aliquots were thawed prior to incubation with glutathione-Sepharose (Amersham Biosciences) for 1 h at room temperature. The Sepharose beads were washed twice with phosphate-buffered saline, 1 mM EDTA, 1% (v/v) Triton X-100 before finally being suspended as a 1:1 slurry. This was used immediately in pulldown assays. Here, dishes (100 mm) of CHO-T cells (8×10^5 cells) were transiently transfected by lipofection (GeneJuice; Novagen) with 2.5 μg of H-Ras cDNA and 1 μg of vector control or vector encoding the particular GAP1 protein. The cells were serum starved for 2 h at 37 °C in serum-free F-12 (HAM; Invitrogen) prior to the experimental procedures. On completion of the manipulation, cells were lysed in 1 ml of ice-cold extraction buffer (50 mM Hepes, pH 7.5, 100 mM NaCl, 1 mM EGTA, 5 μg/ml of benzamidine, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin, 5 μg/ml of pepstatin A, 5 μg/ml of trypsin inhibitor, 0.5 mM phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol containing 1% Triton X-100 and 10 mM $MgCl_2$). Nuclear-free supernatants were incubated with GST-RBD on glutathione-Sepharose beads at 4 °C for 30 min. The beads were then collected by centrifugation and washed three times with ice-cold phosphate-buffered saline, 0.1% Triton X-100, and 10 mM $MgCl_2$. Ras proteins were separated by SDS-PAGE and visualized by immunoblotting on nitrocellulose filters using pan-Ras antibodies (F132; Santa Cruz Biotechnology) and enhanced chemiluminescence (Amersham Biosciences). Blots were analyzed by volume integration using ImageQuant software (Amersham Biosciences) as previously described (22, 24).

Rap1 Pulldown Assays—For the analysis of active Rap, a glutathione *S*-transferase fusion of the Rap-GTP-binding domain from RalGDS (GST-RalGDS) was used (29). Dishes (100 mm) of CHO-T cells (8×10^5 cells) were transiently co-transfected by lipofection (GeneJuice; Novagen) with 2.5 μg of HA-tagged Rap1A cDNA and 1 μg of vector control or vector encoding the particular GAP1 protein. The cells were serum starved for 2 h at 37 °C in serum-free F-12 (HAM) medium 24 h post-transfection prior to stimulation. Cell lysis and Rap1A-GTP pulldown were carried out as described above. Immobilized Rap1A was detected using the HA probe (Y-11; Santa Cruz Biotechnology). Blots were analyzed by volume integration using ImageQuant software (Amersham Biosciences) (22, 24).

RESULTS

Efficient Ras and Rap GAP Activity Requires Structural Elements beyond the Ras GAP Domain of GAP1^{IP4BP}—To extend the published characterization of the Ras and Rap GAP activity of GAP1^{IP4BP} (19, 28), we initially performed a detailed kinetic analysis (Fig. 1). Here, the GAP activity was monitored by following the production of P_i using the charcoal method (15). The isolated GAP domain of GAP1^{IP4BP}, residue 291–569, corresponding to the GAP constructs GAP334 and NF1–333 from p120^{GAP} and neurofibromin, respectively, has pronounced Ras GAP activity that, in contrast to those other Ras GAPs, cannot be saturated under the conditions used (Fig. 1, *A* and *B*). Using 100 nM GAP1^{IP4BP}-(291–569) and 800 μM Ras-GTP, the k_{cat} of the reaction reaches a value of 8 s^{-1}, which is in the range observed for other Ras GAPs (30). Under these conditions, no stimulation of the Rap GTPase was observed. In the presence of 20 μM GAP domain, however, Rap GAP activity was detected (Fig. 1, *C* and *D*) but reached a k_{cat} of only 0.02 s^{-1} with 800 μM Rap-GTP, indicating that the apparent second order rate constant


FIGURE 3. **Ras and Rap1 associate with GAP1^{IP4BP} through the Ras GAP domain *in vitro*.** The GAP activities of the four GAP1^{IP4BP} Ras GAP domain point mutants were assayed using H-Ras or Rap1A. GAP activity is expressed as a percentage of wild-type GAP1^{IP4BP}.

k_{cat}/K_m is at least 2 orders of magnitude lower for the Rap *versus* the Ras GTPase activation. Inefficient hydrolysis is at least partially due to the absence of a glutamine residue in Rap, because with the Rap-(T61Q) mutant, k_{cat} reached 0.5 s^{-1}, which is only 10-fold lower than that observed with Ras (Fig. 1, *A* and *B*).

Because robust Rap GAP activity has been observed before (19) and Ras GAP activity is apparently similar to values observed for other Ras GAPs, it became obvious that GAP1^{IP4BP} requires additional domains for efficient Rap GAP activity. Indeed, when we used full-length GST-GAP1^{IP4BP} enriched via GSH-Sepharose, we observed efficient Ras and Rap GAP activity (Fig. 2). Using 5 nM GAP1^{IP4BP} we observed similar maximal rates of 0.24 μmol/s for Ras and only a 3-fold lower rate of 0.08 μmol/s for Rap (Fig. 2A). Although these rates cannot be converted to k_{cat} values due to the degradation products present in the preparation of the full-length protein, k_{cat} was estimated to be 48 s^{-1} for Ras and 16 s^{-1} for Rap, indicating very efficient catalysis for both GTPase reactions. Furthermore, full-length protein had a 5-fold lower K_m for Rap (42 μM) *versus* Ras (213 μM). Thus the apparent second order rate constant k_{cat}/K_m for the GAP-mediated catalysis, estimated to be between 2.2 and 3.8×10^5 M^{-1} s^{-1}, is, independent of the exact value, very similar for Ras and Rap. This indicates that the additional domain(s) not only affects the catalytic efficiency of the Rap GAP reaction but also dramatically enhances the affinity toward Rap-GTP. Thus, whereas the isolated Ras GAP domain of GAP1^{IP4BP} is, like other Ras GAPs, sufficient to enhance the GTPase activity of Ras, other regions of the molecule such as the amino-terminal C_2 domains and/or the carboxyl-terminal region including the pleckstrin homology/Bruton's tyrosine kinase domain are required for Rap GAP activity.

For Ras GAPs it has been shown that the glutamine 61 residue of Ras and the arginine finger of Ras GAPs are the two crucial residues required for efficient GAP-mediated reaction (13, 14). Rap does not have a glutamine in position 61 and Rap GAP does not act via a catalytic arginine (17), so the question arises as to how GAP1^{IP4BP}-mediated Rap GAP activity is achieved. When we analyze the GTPase reaction using the arginine finger mutant of GAP1^{IP4BP}, GAP1^{IP4BP}-(R371A), the RapGAP (and RasGAP, not shown) activity was severely affected (Fig. 2A), arguing that the basic machinery for GAP activation seems to reside in the GAP domain. As with the GAP domain, catalysis is more efficient for the Rap mutant Rap-(T61Q), but the affinity is reduced because the reaction is no longer saturated with 800 μM Rap-GTP (Fig. 2B). Thus, the mechanism for GAP-mediated GTPase activity of GAP1^{IP4BP} seems to be different from both the Ras GAP and the Rap GAP mechanisms.

FIGURE 4. *In vivo* **GAP1^{IP4BP} also functions as a dual Ras and Rap1 GAP.** *i*, CHO-T cells were transiently co-transfected with 2.5 μg of H-Ras (*A*) or 2.5 μg of HA-tagged Rap1A (*B*) and 1 μg of the relevant GAP1^{IP4BP} expression vector. Compared with control cells, the quantity of Ras- and Rap1-GTP is significantly decreased in cells expressing wild-type GAP1^{IP4BP}. This decrease in Ras- and Rap1-GTP required a functional GAP-related domain (compare *GAP1^{IP4BP}* with *GAP1^{IP4BP}-(L484A)* and *GAP1^{IP4BP}-(R371Q)*). *ii*, quantification of Ras- (*A*) and Rap1-GTP (*B*) levels from CHO-T cells expressed as a percentage of the pulldown in control cells (average of six separate experiments ± S.E.).

Further Mutations in the GAP1^{IP4BP} GAP Domain—To extend this analysis we generated a series of site-directed mutants targeting residues that lie within the Ras-binding site of the Ras GAP domain and are known to be required for the Ras GAP activity of p120^{GAP} and NF1. Arginine at position 485 in GAP1^{IP4BP} is equivalent to arginine 903 and 1391 in p120^{GAP} and NF-1, respectively, residues that by stabilizing the catalytic position of the arginine finger are vital for GTP hydrolysis on Ras (13). The arginine finger is also stabilized by leucine 902 and 1390 in p120^{GAP} and NF-1, respectively, equivalent to leucine 484 in GAP1^{IP4BP}. Furthermore, lysine 949 in p120^{GAP} resides within the variable loop that has been proposed to stabilize the α6c helix within the effector loop region of Ras-GTP. This residue is equivalent to lysine 534 of GAP1^{IP4BP}. Finally, lysine 517 in GAP1^{IP4BP} is equivalent to lysine 935, which has been proposed to stabilize the p120^{GAP}/Ras-GTP complex. To examine the role of these residues in the Ras and Rap GAP activity, we introduced the following individual mutations into full-length GAP1^{IP4BP}: GAP1^{IP4BP}-(L484A), GAP1^{IP4BP}-(R485Q), GAP1^{IP4BP}-(K517E), and GAP1^{IP4BP}-(K534A). As predicted from their conservation with residues critical for the activity of p120^{GAP} and NF-1, all of these mutations lead to a significant decrease in the Ras GAP activity of

GAP1^{IP4BP} (Fig. 3). Interestingly, however, each mutation also resulted in a significantly reduced ability of GAP1^{IP4BP} to function as a Rap GAP (Fig. 3). These data are consistent with a model in which Rap associates with GAP1^{IP4BP} through the Ras-binding domain present in the Ras GAP domain.

GAP1^{IP4BP} Also Displays Dual Ras and Rap1 GAP Activity in Vivo—To confirm the activity described *in vitro* we next examined the GAP activity of GAP1^{IP4BP} *in vivo* using well established pulldown assays for Ras and Rap1 (29). For assays examining Ras GAP activity, CHO-T cells were transiently co-transfected with plasmids encoding for H-Ras and either control plasmid or constructs encoding for GAP1^{IP4BP}. After 24 h cells were serum starved for 2 h prior to quantification of the levels of Ras-GTP following pulldown, using glutathione-Sepharose coupled to a GST fusion of the Ras-GTP-binding domain from Raf-1. Compared with control cells, in those expressing wild-type GAP1^{IP4BP} a significant decrease in the level of Ras-GTP was observed (Fig. 4*A*). This decrease, indicative of an increase in the GTPase activity of this protein, was dependent on the catalytic activity of GAP1^{IP4BP} as GAP1^{IP4BP}-(L484A) was unable to elicit the decrease in Ras-GTP (Fig. 4*A*). Moreover, a site-directed mutant targeting the conserved catalytic arginine finger

FIGURE 5. **In contrast to GAP1^{IP4BP}, GAP1^m appears to function as a specific Ras GAP *in vivo*.** *A, panel i,* CHO-T cells were transiently co-transfected with 2.5 μg of HA-tagged Rap1A and 1 μg of either a control plasmid or the GAP1^m expression vector. In control cells, after 60 s of stimulation with 100 ng/ml EGF the quantity of Rap1-GTP increases 2-fold. In cells expressing GAP1^m no decrease in the quantity of Rap1-GTP was observed irrespective of EGF stimulation (compare *GAP1^m − EGF* with *GAP1^m + EGF*) (*panel ii*). *B, panel i,* CHO-T cells were transiently co-transfected with 2.5 μg of H-Ras and 1 μg of either a control plasmid or the GAP1^m expression vector. In control cells, after 60 s of stimulation with 100 ng/ml EGF the quantity of Ras-GTP increases ~2-fold. In cells expressing Gap1^m a significant decrease in the quantity of Ras-GTP was observed irrespective of EGF stimulation (compare *GAP1^m − EGF* with *GAP1^m + EGF* (*panel ii*)). This decrease in Ras-GTP indicates that the ability of GAP1^m to undergo membrane association is not required for it to function as a Ras GAP. (*panel ii*). Quantification of Rap1- (*A*) and Ras-GTP (*B*) levels from CHO-T cells before and 60 s after stimulation with 100 ng/ml EGF is expressed as a percentage of the pull-down in control, serum-starved cells prior to EGF stimulation (average of six separate experiments ± S.E.).

GAP1^{IP4BP}-(R371Q) was also unable to elicit the decrease in Ras-GTP (Fig. 4*A*). Such data are entirely consistent with GAP1^{IP4BP} functioning as a Ras GAP *in vivo*.

To analyze the potential *in vivo* Rap1 GAP activity, CHO-T cells were transiently co-transfected with plasmids encoding for Rap1 and either control plasmid or constructs encoding for GAP1^{IP4BP} (Fig. 4*B*). After 24 h cells were serum starved for 2 h prior to quantification of the levels of Rap1-GTP following pulldown, using glutathione-Sepharose coupled to a GST fusion of the RBD domain from RalGDS (29). Consistent with the *in vitro* data, in cells expressing GAP1^{IP4BP} a significant decrease in the level of Rap1-GTP was observed. This decrease in recoverable Rap1-GTP was not observed in those cells expressing GAP1^{IP4BP}-(L484A) or the arginine finger mutant GAP1^{IP4BP}-(R371Q) (Fig. 4*B*).

GAP1^m Appears to Function as a Specific Ras GAP in Vivo—An outstanding issue concerns whether this ability to function as a dual Ras and Rap GAP is restricted to GAP1^{IP4BP} or whether it is a property of other GAP1 family members. Previous work has demonstrated that *in vitro* GAP1^m displays GAP activity against Ras but not Rap1 (28). However, given the subsequent demonstration that GAP1^m undergoes a receptor-mediated association with the plasma membrane as a result of its pleckstrin homology/Bruton's tyrosine kinase domain associating with phosphatidylinositol 3,4,5-trisphosphate (21), we examined whether *in vivo* GAP1^m was capable of functioning as a Rap1 GAP following such a receptor-mediated plasma membrane association. In

CHO-T cells transiently co-transfected with plasmids encoding Rap1 and either control plasmid or constructs encoding GAP1^m, no detectable drop in the level of Rap1-GTP was observed in those cells expressing GAP1^m (Fig. 5*A*). In parallel experiments examining the GAP activity against Ras, a clear decrease in the level of Ras-GTP was observed (Fig. 5*B*); these data confirm the previous *in vitro* study of GAP1^m (28). To examine whether the plasma membrane association of GAP1^m stimulated its ability to function as a Rap1 GAP, serum-starved cells were stimulated with epidermal growth factor (EGF), an agonist that induces the plasma membrane association of GAP1^m (21). Under these conditions, still no detectable decrease in the level of Rap1 GTP was observed (Fig. 5*A*). These data suggest that unlike GAP1^{IP4BP}, GAP1^m does not display detectable Rap1 GAP activity *in vivo* when assayed under these conditions.

*In Contrast to GAP1^m, RASAL Displays Dual Ras and Rap1 GAP Activity in Vivo*—The remaining GAP1 family members, CAPRI and RASAL, are cytosolic proteins that undergo a rapid Ca^{2+}-induced association with the plasma membrane following receptor activation (22, 24, 25). This recruitment, which results from their C$_2$ domains binding phospholipids in a Ca^{2+}-dependent manner, increases their Ras GAP activity (22, 24, 25). To examine whether these proteins display Rap GAP activity, we initially transiently co-transfected CHO-T cells with Rap1 and RASAL. In those cells expressing RASAL a significant decrease in the amount of Rap1-GTP was observed compared with

FIGURE 6. **RASAL appears to function as a constitutively active Rap GAP.** *A*, CHO-T cells were transiently co-transfected with 2.5 μg of HA-tagged Rap1A and 1 μg of the relevant RASAL expression vector. In control cells, after 60 s of stimulation with 50 μM ATP the quantity of Rap1-GTP increased 2-fold. In cells expressing Rap1A and wild-type RASAL a significant decrease in the quantity of Rap1-GTP was observed before and after stimulation with ATP (compare *RASAL − ATP* with *RASAL + ATP*). This decrease in Rap-GTP required a functional GAP-related domain but does not appear to require the ability of RASAL to undergo Ca^{2+}-induced membrane association (compare *RASAL* with *RASAL-(Q507N)* and *RASAL-(D202A)*). *B*, quantification of Rap1-GTP levels from CHO-T cells before and 60 s after stimulation with 50 μM ATP expressed as a percentage of the pulldown in control, serum-starved cells prior to ATP stimulation (average of ten separate experiments ± S.E.).

FIGURE 7. **CAPRI displays an ability to function as a Ca^{2+}-regulated Rap GAP.** *A*, CHO-T cells were transiently co-transfected with HA-tagged Rap1A and 1 μg of expression vector containing either wild-type CAPRI or CAPRI(D202A) (22). In control cells, after 60 s of stimulation with 50 μM ATP the quantity of Rap1-GTP was increased. In cells expressing Rap1A and CAPRI a significant decrease in the quantity of Rap1-GTP was observed after 60 s of stimulation with ATP (compare *CAPRI − ATP* with *CAPRI + ATP*). This decrease in Rap1-GTP was not observed in ATP-stimulated cells expressing the CAPRI-(D202A) mutant (compare *CAPRI + ATP* with *CAPRI-(D202A) + ATP*). *B*, quantification of Rap1-GTP levels from CHO-T cells before and 60 s after stimulation with 50 μM ATP expressed as a percentage of the pulldown in control, serum-starved cells prior to ATP stimulation (average of five separate experiments ± S.E.).

controls (Fig. 6). This basal Rap GAP activity was dependent on the Ras GAP domain, as expression of RASAL-(Q507N) had no effect on Rap1-GTP levels, but was independent of the Ca^{2+}/phospholipid-binding C$_2$ domains; RASAL-(D202A) is a C$_2$ domain mutant unable to undergo Ca^{2+}-induced membrane association (24) (Fig. 6). These data suggest that *in vivo* when localized to the cytosol RASAL has a basal Rap GAP activity.

To establish the role of membrane association in the control of the Rap GAP activity, we examined the ability of RASAL to function as a Rap GAP following stimulation with ATP, an agonist that elevates intracellular free Ca^{2+} and induces the plasma membrane association of RASAL (24). In control serum-starved cells, addition of ATP induced an increase in Rap1-GTP levels (Fig. 6). In cells expressing RASAL the ATP-induced elevation in Rap1-GTP was significantly reduced (Fig. 6). Interestingly, the ability of RASAL to decrease the ATP-induced elevation in Rap1-GTP, although clearly dependent on the Ras GAP domain (see RASAL-(Q507N)), was independent of the Ca^{2+}-induced membrane translocation as RASAL-(D202A) reduced the ATP-stimulated

increase in Rap1-GTP to a similar level as wild-type protein (Fig. 6). Taken with previous data (24) these results establish that *in vivo* RASAL acts as a dual Ras and Rap GAP. However, whereas its Ras GAP activity is dependent on its Ca^{2+}-induced plasma membrane translocation (24), the Rap GAP activity appears to be irrespective of such a membrane association.

CAPRI Also Has Dual Ras and Rap GAP Activity—Given the sequence similarity between RASAL and the Ca^{2+}-regulated Ras GAP CAPRI (22, 24, 25), we also examined the ability of the latter to function as a Rap GAP (Fig. 7). Here, the basal level of Rap1-GTP was not significantly affected by overexpression of CAPRI. However, in parallel experiments to those described above, the ATP-induced elevation in Rap1-GTP was significantly reduced in CAPRI-expressing CHO-T cells (Fig. 7). This increase in Rap1 GAP activity required the ability of CAPRI to associate with the plasma membrane as CAPRI-(D202A), a C$_2$ domain mutant unable to undergo Ca^{2+}-induced plasma membrane association (data not shown), failed to decrease the ATP-induced elevation in Rap1-GTP (Fig. 7). Thus, CAPRI can function as a dual Ras and Rap GAP, but

in contrast to RASAL the latter activity is only detectable upon the Ca^{2+}-induced plasma membrane association.

DISCUSSION

In this study, detailed kinetic analysis has demonstrated that full-length, recombinant GAP1^{IP4BP} possesses a robust Ras and Rap GAP activity, with estimated k_{cat}s of 16 and 48 s^{-1} and K_ms of 42 and 213 μM for Rap and Ras, respectively. These values are very similar for the two GTPase substrates and are in the range of values for known specific Ras and Rap GAPs. The Ras-specific GAPs, NF1 and p120^{GAP}, have K_m values of 0.23 and 5.0 μM and k_{cat}s of 5.4 and 8.0 s^{-1} on H-Ras, respectively (30), whereas Rap1 GAP, a Rap-specific GAP, has a k_{cat} of 5.6 s^{-1} and a K_m of 52 μM for Rap (15). Thus, GAP1^{IP4BP} has similar activity toward the individual small GTPases, but, unlike NF1, p120^{GAP}, and Rap1 GAP, it has retained both of these activities within a singular molecular entity.

How is such a dual activity achieved? At present we cannot define the details of the actual mechanism. This will require further work. However, it is clear that although the isolated Ras GAP domain retains Ras GAP activity (this is consistent with the same domain having Ras GAP activity in NF1 and p120^{GAP}) the isolated GAP1^{IP4BP} Ras GAP domain loses its efficiency as a Rap GAP. These data point to other regions outside the GAP domain being required to support the catalytic activity toward Rap. Indeed, for other GAP molecules there is evidence that additional domains are required to regulate the catalytic activity (31–33). Although the absence in Rap of the Gln-61 residue of Ras is partially responsible for the lower catalytic activity of both the GAP domain and full-length protein, its presence in the T61Q mutant of Rap also influences the affinity toward GAP in opposite ways, by increasing the affinity in the GAP domain and decreasing it in full-length protein. Structural studies will be required to understand these observations in mechanistic terms.

Our analysis of various site-directed mutants, some of which target residues within the predicted Ras binding region of the GAP domain, is consistent with Rap associating with GAP1^{IP4BP} through the conserved Ras-binding site. This conclusion, not unexpected given that Rap-GTP associates with p120^{GAP} through the Ras-binding site (although obviously in this case the GTPase activity of Rap1 is not enhanced), argues that GAP1^{IP4BP} cannot function simultaneously as a Ras and Rap GAP. In other words, at any one time GAP1^{IP4BP} will only stimulate the GTPase activity of either Ras or Rap. At present we do not know whether additional factors, such as phosphorylation, association with particular phospholipids, or other protein-protein interactions, modulate the preference for Ras *versus* Rap GAP. However, given the precedent that all of these modes of modulation have been proposed to regulate the catalytic activity of a wide variety of GAP proteins (reviewed in Ref. 10), it is tempting to speculate that one or more of these mechanisms may differentially regulate the activity of GAP1^{IP4BP}. Clearly, such modulatory mechanisms will have an important bearing on the physiological function of GAP1^{IP4BP}.

Besides GAP1^{IP4BP}, our data establish that, with the possible exception of GAP1^m, all members of the GAP1 family act as dual Ras and Rap GAPs. For these proteins the ability to display their particular GAP activity is controlled by distinct second messenger pathways, GAP1^{IP4BP} being controlled by phosphoinositides (19, 34, 35) and CAPRI and RASAL modulated to differing degrees by receptor-mediated increases in $[Ca^{2+}]_i$ (Refs. 22,24,25, and the present study). This argues for a complex interplay between these second messenger pathways and the modulation of Ras and Rap signaling. This is particularly true for increases in $[Ca^{2+}]_i$ (36).

It has long been recognized that increases in $[Ca^{2+}]_i$ can regulate Ras and Rap1 activation. Only recently, however, have molecular entities been described through which this regulation may occur (reviewed in Ref. 35). In the context of the present study, the CalDAG-GEF/GRP family of exchange factors is of particular interest. Members of this family have Ca^{2+}- and diacylglycerol-binding sites and are regulated by one or both of these messenger molecules (4–6). For CalDAG-GEFI, and also GRP2 and GRP3, there is evidence that receptor-mediated increases in $[Ca^{2+}]_i$ and diacylglycerol stimulate the ability of these proteins to function as dual exchange factors for Ras and Rap (4, 36, 37). These data, taken with the ability of Ca^{2+} to regulate the Ras and Rap GAP activity of CAPRI and RASAL, suggest that receptor-mediated increases in $[Ca^{2+}]_i$ may constitute a complex means by which cells can modulate the relative activation profiles of Ras and Rap during receptor activation (38). In this regard it is interesting to note that Ras and Rap have been proposed to function independently, but in a coordinated manner, in delivering and removing α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors from the post-synaptic membrane during long-term potentiation and long-term depression (39). An important modulator of such synaptic plasticity is SynGAP (40, 41), a Ras GAP whose activity appears to be modulated through Ca^{2+}/calmodulin-dependent protein kinase II (CaMKII) (42, 43). Interestingly, this protein has also been shown to have Rap GAP activity (43), although it remains to be established what, if any, effect CaMKII-mediated phosphorylation has on the relative Ras *versus* Rap GAP activity. Like the GAP1 proteins discussed in this study, SynGAP may well constitute a molecular machine that can coordinate changes in the activation profiles of these two small GTPases.

Finally, the identification of RASAL and CAPRI as candidate tumor suppressors (44, 45) and the proposed role of CAPRI in innate immunity (46) have increased interest in the biology of these proteins. The data presented here argue that when considering the function of RASAL and CAPRI one needs to consider not only their Ras GAP activity but also their ability to inactivate Rap1 signaling.

REFERENCES

1. Shields, J. M., Pruitt, K., McFall, A., Shaub, A., and Der, C. J. (2000) *Trends Cell Biol.* **10,** 147–153
2. Hancock, J. F. (2003) *Nat. Rev. Mol. Cell Biol.* **4,** 373–384
3. Bos, J. L. (2005) *Curr. Opin. Cell Biol.* **17,** 123–128
4. Stork, P. J. S. (2003) *Trends Biochem. Sci.* **28,** 267–275
5. Caron, E. (2003) *J. Cell Sci.* **116,** 435–440
6. Hattori, M., and Minato, N. (2003) *J. Biochem.* **134,** 479–484
7. Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y., and Noda, M. (1989) *Cell* **56,** 77–84
8. Donovan, S., Shannon, K. M., and Bollag, G. (2002) *Biochim. Biophys. Acta* **1602,** 23–45
9. Bernards, A. (2003) *Biochim. Biophys. Acta* **1603,** 47–82
10. Bernards, A., and Settleman, J. (2004) *Trends Cell Biol.* **14,** 377–385
11. Yajnik, V., Paulding, C., Sordella, R., McClatchey, A. I., Saito, M., Wahrer, D. C. R., Reynolds, P., Bell, D. W., Lake, R., van den Heuvel, S., Settleman, J., and Haber, D. A. (2003) *Cell* **112,** 673–684
12. Scheffzek, K., Lautwein, A., Kabsch, W., Ahmadian, M. R., and Wittinghofer, A. (1996) *Nature* **384,** 591–596
13. Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmuller, L., Lautwein, A., Schmitz, F., and Wittinghofer, A. (1997) *Science* **277,** 333–338
14. Ahmadian, M. R., Stege, P., Scheffzek, K., and Wittinghofer, A. (1997) *Nat. Struct. Biol.* **4,** 686–689
15. Brinkmann, T., Daumke, O., Herbrand, U., Kuhlmann, D., Stege, P., Ahmadian, M. R., and Wittinghofer, A. (2002) *J. Biol. Chem.* **277,** 12525–12531
16. Chakrabarti, P. P., Suveyzdis, Y., Wittinghofer, A., and Gerwert, K. (2004) *J. Biol. Chem.* **279,** 46226–46233

17. Daumke, O., Weyand, M., Chakrabarti, P. P., Vetter, I. R., and Wittinghofer, A. (2004) *Nature* **429,** 197–201
18. Maekawa, M., Iwamatsu, S. A., Morishita, T., Yokota, K., Imai, Y., Kohsaka, S., Nakamura, S., and Hattori, S. (1994) *Mol. Cell. Biol.* **14,** 6879–6885
19. Cullen, P. J., Hsuan, J. J., Truong, O., Letcher, A. J., Jackson, T. R., Dawson, A. P., and Irvine, R. F. (1995) *Nature* **376,** 527–530
20. Allen, M., Chu, S., Brill, S., Stotler, C., and Buckler, A. (1998) *Gene* **218,** 17–25
21. Lockyer, P. J., Wennstrom, S., Kupzig, S., Venkateswarlu, K., Downward, J., and Cullen, P. J. (1999) *Curr. Biol.* **9,** 265–268
22. Lockyer, P. J., Kupzig, S., and Cullen, P. J. (2001) *Curr. Biol.* **11,** 981–986
23. Cullen, P. J. (1998) *Biochim. Biophys. Acta* **1436,** 35–47
24. Walker, S. A., Kupzig, S., Bouyoucef, D., Davies, L. C., Tsuboi, T., Bivona, T., Cozier, G. E., Lockyer, P. J., Buckler, A., Rutter, G. A., Allen, M. J., Philips, M. R., and Cullen, P. J. (2004) *EMBO J.* **23,** 1749–1760
25. Liu, Q., Walker, S. A., Gao, D., Taylor, J. A., Dai, Y-F., Arkell, R. S., Bootman, M. D., Roderick, H. L., Cullen, P. J., and Lockyer, P. J. (2005) *J. Cell Biol.* **170,** 183–190
26. Tucker, J., Sczakiel, G., Feuerstein, J., John, J., Goody, R. S., and Wittinghofer, A. (1986) *EMBO J.* **5,** 1351–1358
27. John, J., Frech, M., and Wittinghofer, A. (1988) *J. Biol. Chem.* **263,** 11792–11799
28. Bottomley, J. R., Reynolds, J. S., Lockyer, P. J., and Cullen, P. J. (1998) *Biochem. Biophys. Res. Commun.* **250,** 143–149
29. Franke, B., Akkerman, J. W., and Bos, J. L. (1997). *EMBO J.* **16,** 252–259
30. Ahmadian, M. R., Hoffmann, U., Goody, R. S., and Wittinghofer, A. (1997) *Biochemistry* **36,** 4535–4541
31. Drugan, J. K., Rogers-Graham, K., Gilmer, T., Campbell, S., and Clark, G. J. (2000) *J. Biol. Chem.* **275,** 35021–35027
32. Fauchereau, F., Herbrand, U., Chafey, P., Eberth, A., Koulakoff, A., Vinet, M. C., Ahmadian, M. R., Chelly, J., and Billuart, P. (2003) *Mol. Cell. Neurosci.* **23,** 574–586
33. Moskwa, P., Paclet, M-H., Dagher, M-C., and Ligeti, E. (2005) *J. Biol. Chem.* **280,** 6716–6720
34. Lockyer, P. J., Bottomley, J. R., Reynolds, J. S, McNulty, T. J., Venkateswarlu, K., Potter, B. V. L., Dempsey, C. E., and Cullen, P. J. (1997) *Curr. Biol.* **7,** 1007–1010
35. Cozier, G. E., Lockyer, P. J., Reynolds, J. S., Kupzig, S., Bottomley, J. R., Millard, T. M., Banting, G., and Cullen, P. J. (2000) *J. Biol. Chem.* **275,** 28261–28268
36. Cullen, P. J., and Lockyer, P. J. (2002) *Nat. Rev. Mol. Cell Biol.* **3,** 339–348
37. Bos, J. L., de Rooij, J., and Reedquist, K. A. (2001) *Nat. Rev. Mol. Cell Biol.* **2,** 369–377
38. Kupzig, S., Walker, S. A., and Cullen, P. J. (2005) *Proc. Natl. Acad. Sci. U. S. A.* **102,** 7577–7582
39. Zhu, J. J., Qin, Y., Zhao, M., Van Aelst, L., and Malinow, R. (2002) *Cell* **110,** 443–455
40. Chen, H. J., Rojas-Soto, M., Oguni, A., and Kennedy, M. B. (1998) *Neuron* **20,** 895–904
41. Kim, J. H., Liao, D. Z., Lau, L. F., and Huganir, R. L. (1998) *Neuron* **20,** 683–691
42. Oh, J. S., Manzerra, P., and Kennedy, M. B. (2004) *J. Biol. Chem.* **279,** 17980–17988
43. Krapivinsky, G., Medina, I., Krapivinsky, I., Gapon, S., and Clapham, D. E. (2004) *Neuron* **43,** 563–574
44. Kolfschoten, I. G. M., van Leeuwen, B., Berns, K., Mullenders, J., Beijersbergen, R. L., Bernards, R., Voorhoeve, P. M., and Agami, R. (2005) *Cell* **121,** 849–858
45. Westbrook, T. F., Martin, E. S., Schlabach, M. R., Leng, Y. M., Liang, A. C., Feng, B., Zhao, J. J., Roberts, T. M., Mandel, G., Hannon, G. J., DePinho, R. A., Chin, L., and Elledge, S. J. (2005) *Cell* **121,** 837–848
46. Zhang, J., Guo, J., Dzhagalov, I., and He, Y-W. (2005). *Nat. Immunol.* **6,** 911–919